Management prevention

COVID-19
Chairs: T. Welte (Hannover, Germany)
Aims: This session will explain the public health approaches recommended by the European Centre for Disease Prevention and Control (ECDC) including surveillance, epidemic intelligence, response, preparedness, training, and communication. This session will also describe the different vaccine approaches (whole-virus, genetic, viral vector, protein based) and highlight key vaccine clinical trials currently underway. Key references: 1: Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 Jul 20:S0140-6736(20)31604-4. doi: 10.1016/S0140-6736(20)31604-4. Epub ahead of print. PMID: 32702298.

Public health approaches P. Penttinen (Stockholm, Sweden)
Immunology underpinning vaccine strategy: what is the risk of reinfection? P. Openshaw (London, United Kingdom)
Vaccines - early clinical trials G. Karakiulakis (Thessaloniki, Greece)